Difference between revisions of "CNS melanoma"
Jump to navigation
Jump to search
(Created page with "<!--'''Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer. If th...") |
(dose correction) |
||
| Line 39: | Line 39: | ||
|} | |} | ||
====Immunotherapy, part 1==== | ====Immunotherapy, part 1==== | ||
| − | *[[Ipilimumab (Yervoy)]] | + | *[[Ipilimumab (Yervoy)]] 3 mg/kg IV once on day 1 |
| − | *[[Nivolumab (Opdivo)]] | + | *[[Nivolumab (Opdivo)]] 1 mg/kg IV once on day 1 |
'''21-day cycle for 4 cycles, followed by:''' | '''21-day cycle for 4 cycles, followed by:''' | ||
| Line 50: | Line 50: | ||
===References=== | ===References=== | ||
| − | # '''ANZMTG 01.14:''' Long GV, Atkinson V, Lo S, Sandhu S, Guminski AD, Brown MP, Wilmott JS, Edwards J, Gonzalez M, Scolyer RA, Menzies AM, McArthur GA. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol. 2018 Mar 27. | + | # '''ANZMTG 01.14:''' Long GV, Atkinson V, Lo S, Sandhu S, Guminski AD, Brown MP, Wilmott JS, Edwards J, Gonzalez M, Scolyer RA, Menzies AM, McArthur GA. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol. 2018 Mar 27. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30139-6/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29602646 PubMed] |
[[Category:CNS melanoma regimens]] | [[Category:CNS melanoma regimens]] | ||
[[Category:Disease-specific pages]] | [[Category:Disease-specific pages]] | ||
[[Category:CNS cancers]] | [[Category:CNS cancers]] | ||
Revision as of 12:16, 4 May 2018
| Section editors | |||
|---|---|---|---|
 |
Seema Nagpal, MD Palo Alto, CA |
 |
Elizabeth Buchbinder, MD Boston, MA |
5 regimens on this page
5 variants on this page
|
Guidelines
NCCN
All lines of therapy
Ipilimumab & Nivolumab
| back to top |
Regimen
| Study | Evidence | Comparator |
|---|---|---|
| Long et al. 2018 (ANZMTG 01.14) | Randomized Phase II | Nivolumab |
Immunotherapy, part 1
- Ipilimumab (Yervoy) 3 mg/kg IV once on day 1
- Nivolumab (Opdivo) 1 mg/kg IV once on day 1
21-day cycle for 4 cycles, followed by:
Immunotherapy, part 2
- Nivolumab (Opdivo) 3 mg/kg IV over 60 minutes once on day 1
14-day cycles
References
- ANZMTG 01.14: Long GV, Atkinson V, Lo S, Sandhu S, Guminski AD, Brown MP, Wilmott JS, Edwards J, Gonzalez M, Scolyer RA, Menzies AM, McArthur GA. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol. 2018 Mar 27. link to original article contains verified protocol PubMed